Eli Lilly and Boehringer Ingelheim will undercut Sanofi by 15% with Basaglar, a biosimilar version of the insulin blockbuster Lantus launched today in the US. Basaglar will also undercut Sanofi ...

Lilly and Boehringer Ingelheim have gained EU approval for their biosimilar version of Sanofi's blockbuster insulin product Lantus (insulin glargine). The Europe-wide approval is the first ever ...

Eli Lilly (NYSE:LLY) on Thursday announced that ... A1C stood at 1.31% for efsitora compared to 1.27% for insulin glargine at Week 52, indicating non-inferiority. Meanwhile, at Week 26, the ...

Eli Lilly has reported positive outcomes from the ... In the QWINT-4 trial, efsitora's efficacy and safety were measured against insulin glargine over 26 weeks in patients previously treated ...